Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Share-based Compensation (2017 - 2025)

VYNE Therapeutics (VYNE) has disclosed Share-based Compensation for 9 consecutive years, with $529000.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Share-based Compensation fell 40.23% year-over-year to $529000.0, compared with a TTM value of $2.7 million through Jun 2025, down 20.85%, and an annual FY2025 reading of $2.3 million, down 30.12% over the prior year.
  • Share-based Compensation was $529000.0 for Q2 2025 at VYNE Therapeutics, down from $763000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $2.4 million in Q1 2021 and bottomed at $529000.0 in Q2 2025.
  • Average Share-based Compensation over 5 years is $1.1 million, with a median of $889000.0 recorded in 2022.
  • Peak annual rise in Share-based Compensation hit 38.83% in 2021, while the deepest fall reached 82.35% in 2021.
  • Year by year, Share-based Compensation stood at $1.3 million in 2021, then fell by 19.89% to $1.1 million in 2022, then plummeted by 33.46% to $710000.0 in 2023, then decreased by 1.55% to $699000.0 in 2024, then decreased by 24.32% to $529000.0 in 2025.
  • Business Quant data shows Share-based Compensation for VYNE at $529000.0 in Q2 2025, $763000.0 in Q1 2025, and $699000.0 in Q4 2024.